`
`
`
`DEPARTMENT OF HEALTH AND HUMAN SERVICES
`
`
`
`
`
`
`
` NDA 019516/S-043
`
` NDA 022272/S-023
`
`
`
`
`
`
`Food and Drug Administration
`
`
` Silver Spring MD 20993
`
`SUPPLEMENT APPROVAL
`
`
` Purdue Pharma, L.P.
`
` One Stamford Forum
`
` Stamford, CT 06901-3431
`
`
`
`
`Attention: Beth Connelly
`
`
`Associate Director, Regulatory Affairs
`
`
`
`
`Dear Ms. Connelly:
`
`
`
`
`
`
`Please refer to your Supplemental New Drug Applications (sNDAs) dated April 17, 2014,
`
`
`
`
`
`received April 23, 2014, submitted under section 505(b) of the Federal Food, Drug, and
`
`Cosmetic Act (FDCA) for MS CONTIN (morphine sulfate extended-release tablets) and
`
`
`OXYCONTIN (oxycodone hydrochloride extended-release tablets).
`
`
`
`
`
`
`
`These “Changes Being Effected” supplemental new drug applications provide for revised
`
`
`
`immediate container labels for both drugs as well as revised carton labels and blister packs for
`
`OXYCONTIN. The revisions include changing the dosage form from “controlled-release
`
`
`
`
`tablets” to “extended-release tablets,” and changing the established name and dosage form
`
`expression from “ (drug substance controlled-release) Tablets” to “ (drug substance extended-
`
`
`release tablets)” to conform with FDA and USP current standards.
`
`
`APPROVAL & LABELING
`
`We have completed our review of this supplemental application and it is approved, effective on
`
`
`
`
`
`the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.
`
`
`
`CARTON AND IMMEDIATE CONTAINER LABELS
`
`
`
`We acknowledge your April 17, 2014, submissions containing final printed carton and container
`
`
`
`labels for MS CONTIN and OXYCONTIN Tablets.
`
`
`
`
`
`REPORTING REQUIREMENTS
`
`
`We remind you that you must comply with reporting requirements for an approved NDA
`
`
`
`(21 CFR 314.80 and 314.81).
`
`
`
`
`Reference ID: 3646951
`
`
`
`
`
`
`
`
`
`
`Sincerely,
`
`
`{See appended electronic signature page}
`
`
`Sharon Hertz, MD
`
`Acting Director
`
`
`Division of Anesthesia, Analgesia,
`
`
`and Addiction Products
`
`
`Office of Drug Evaluation II
`
`Center for Drug Evaluation and Research
`
`
`
` NDA 019516/S-043
`
` NDA 022272.S-023
`
` Page 2
`
`
` If you have any questions, call Lisa Basham, Senior Regulatory Health Project Manager, at (301)
`
`
` 796-1175.
`
`
`
`
`
`
`
`
`ENCLOSURE:
`
`
`
`Carton and Container Labels
`
`
`Reference ID: 3646951
`
`
`
`---------------------------------------------------------------------------------------------------------
`This is a representation of an electronic record that was signed
`electronically and this page is the manifestation of the electronic
`signature.
`---------------------------------------------------------------------------------------------------------
`/s/
`----------------------------------------------------
`
`SHARON H HERTZ
`10/22/2014
`
`Reference ID: 3646951
`
`